Global emergency by Vijayan, V K
109
EDITORIAL
“GLOBAL EMERGENCY”
Mycobacterium tuberculosis described by
Robert Koch in 1882 is the leading infectious killer of
adults (1). The World Health Organisation (WHO) has
estimated that there are nearly 1.7 billion individuals
infected with Mycobacterium tuberculosis throughout the
world, approximately 20 million of these are active cases
and three million die each year. Eight million new cases
occur each year and three million of these are infectious
(2). The WHO has predicted that, if worldwide
tuberculosis (TB) control programme is not improved, 90
million new cases and 30 million deaths can be expected
in the decade 1990-1999 (3,4). Of the 950 million
inhabitants in India, 300 million are infected with
M. tuberculosis, 12 million have active tuberculosis, three
million are infectious and half a million die each year (5).
Two decades ago, the goal of industrialized countries
with low prevalence of tuberculosis was the eradication
or the elimination of tuberculosis. Elimination is possible,
if the rate of infection is less than 1% in the general
population or there is only one smear-positive case per
million inhabitants. However, in many industrialized
countries, the downward trend in tuberculosis rates has
been either stabilized or even slightly reversed. Several
factors including the closing of TB clinics, economic
crisis, demographic reasons, HIV/AIDS epidemic and
population migration contributed to this phenomenon.
Since Robert Koch’s discovery of TB bacilli in 1882, at
least 200 million people especially those in the most
economically productive years of life had died due to
tuberculosis (6). Realizing the gravity of the problem,
the WHO in 1993 declared tuberculosis as a global
emergency. This has led to worldwide resurgence in
research in tuberculosis. Indian scientists are also
actively pursuing research in tuberculosis and this is
reflected by the three articles on tuberculosis appearing
in this issue of the journal (7-9).
The discovery of streptomycin purified from
Streptomyces grieseus in 1943 by Selman A. Waksman
laid the foundation of modern chemotherapy of
tuberculosis. Subsequently, other anti-TB drugs such as
p-amino-salicylic acid (1949), isoniazid (1952),
pyrazinamide (1954) cycloserine (1955), ethambutol
(1962) and rifampicin (1963) were discovered. The
problem of resistant mutants due to monotherapy was
overcome by the use of two or three anti-TB drugs. Indian
scientists in collaboration with western scientists
especially from British Medical Research Council have
made significant contributions in tuberculosis. These
include the demonstration that home treatment is as good
as sanatorium treatment (10), development of supervised
intermittent regimens (11), the importance of bacteriology
in the diagnosis of TB (12) the BCG trial in south India
(13) and the formulation of nationally applicable, socially
acceptable and epidemiologically effective National
Tuberculosis Programme (14,15). This has been
reflected in the statement: “The world owes a debt of
gratitude to India for its research in the field of TB” (16).
HIV/AIDS epidemic has a devastating effect on
tuberculosis. In most immuno-competent individuals,
infection with M. tuberculosis will not lead to progressive
disease, although living bacteria are not eliminated. HIV
specifically infects and destroys CD,+ T ceils (17).
HIV+ve individuals become susceptible both to
reactivation of latent infection with M. tuberculosis and to
rapid progression to disease following a new infection.
In immunocompetent individuals infected with
M. tuberculosis, the life time risk of developing active
tuberculosis is 10%. Persons, who have prior infection
with M. tuberculosis and acquire HIV infection later, have
a risk of 10% per year of developing active tuberculosis.
However, if a person with AIDS is exposed and infected
with tuberculosis, he/she has a 40 % chance of
developing active tuberculosis within a few months (18).
Adult patients with TB and HIV infection in the initial
stages present with classical post-primary disease
affecting upper parts of the lungs and with cavities and
necrosis. As the immuno-deficiency progresses, atypical
features such as involvement of middle and lower lobes
of the lungs, noncavitary disease and dissemination of
the disease are encountered(19). The change from
cavitary pulmonary disease to noncavitary disease is
associated with a lower bacillary load. Therefore, it will
be difficult to establish the diagnosis in such situation
because sputum smear examination is often negative
and the clinical presentations resemble the childhood
tuberculosis (20). HIV+ve patients with TB respond well
to treatment, but adverse drug reactions especially to
thiacetazone are common (21). Even though response
to treatment in HIV+ve TB patient is good, mortality is
high. M. tuberculosis has been shown to stimulate HIV
replication in macrophages through the release Of
cytokines (22). TB may, thus, cause acceleration of the
progression of HIV disease and reduce life expectancy.
lsoniazid preventive therapy has been found to be
effective in preventing tuberculosis in HIV infected
individuals (23). However, optimum duration and cost-
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effectiveness of preventive therapy are yet to be
established. Other factors, in addition to HIV/AIDS, that
increase the risk of tuberculosis include silicosis (24),
malignancies (25), hemophilia (26), renal failure (27),
body build (28), gastrectomy (29), diabetes (30), jejuno-
ileal bypass (31), certain human leucocyte antigen (HLA)
types (32) certain blood groups (33), smoking (34),
corticosteroid treatment (35) pregnancy or postpartum
period (36) and measles (37).
Microscopic examination of sputum smears for
AFB devised by Robert Koch more than a century ago
continues to be the most important diagnostic test in
tuberculosis (38). Even though M. tuberculosis culture is
the gold standard for the diagnosis, it is time consuming
and expensive and is not practicable for routine
management of patients. Radiometric method such as
BACTEC system, though provides rapid results (average,
9 days) is also expensive and cannot be applicable in
our country, except in a few referral centres (39). The
new diagnostic tests (40) that are being evaluated include
improved AFB detection by immunomagnetic separation
strategy, detection of mycobacterial components
(tuberculo-stearic acid, 2-eicosanol etc.), signal
amplification methods (branched DNA signal
amplification , Qß signal amplification and reporter phage
systems) and target amplification methods (polymerase
chain reaction (PCR) amplification, RNA amplification,
strand displacement amplification and ligase chain
reaction amplification). A serological test that aids in the
diagnosis of smear negative and extrapulmonary
tuberculosis is not currently available (41). Childhood
pulmonary tuberculosis is managed clinically because
of the absence of a reliable diagnostic test. We had
demonstrated that gastric lavage was better than
bronchoalveolar lavage for bacteriologic diagnosis of
childhood pulmonary tuberculosis (42).
The emergence of multidrug resistant (MDR)
strains due to careless TB treatment practices, is a real
threat to TB control programme (43). The diagnosis of
MDR-TB in an individual is a virtual death sentence. MDR-
TB is defined as resistance of M. tuberculosis to the
antimicrobial activity of more than one of any anti-TB
drugs. Currently, MDR-TB is synonymous with resistance
to the two most effective anti-TB drugs, Viz: isoniazid
and rifampicin. Molecular basis of drug resistance in TB
includes the following features: i) deletion or mutation of
the Kat G gene or modification of inh A gene in isoniazid
resistance, ii) mutations in rpoß gene in rifampian
resistance, iii) mutations in rpsl or rrs genes in
streptomycin resistance and iv) mutations in gyr A or gyr
B genes in fluoroquinolone resistance (44). There is a
suggestion that MDR-TB is increasing in India (45-47).
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The availability of drugs with high bactericidal
activity and with capacity to inhibit the development of
resistance has made it possible to evolve potent short
course chemotherapy regimens for treatment of
tuberculosis (48). Short course chemotherapy of six
months duration has been found to be more cost-effective
than 12-18 months of treatment (49). When MDR-TB is
suspected, it is important to use four or five agents to
ensure that patients receive at least two drugs to which
organisms are likely to be sensitive (43). Resurgence of
tuberculosis has focussed attention on the development
of new anti-TB drugs that include rifamycin derivatives,
fluoroquinolones, clofazimine, combination of betalactam
antibiotics and beta-lactamase inhibitors and new
macrolides (50,51). The role of BCG vaccination in
controlling TB is controversialwith trials reporting efficacy
rates between 0% and 80% (52,513). However,
vaccination of newborns with BCG is recommended, as
there are evidences that BCG provides reasonable levels
of protection against childhood forms of TB and against
leprosy (53,54).
The Worldwide resurgence in tuberculosis has
prompted the WHO and many nations to evolve new
strategies to control tuberculosis. A Revised National
Tuberculosis Programme (RNTP) is being pilot tested in
selected cities and states in India (55). The RNTP
envisages introduction of short course chemotherapy and
administration of anti-TB drugs under supervision by a
health worker during intensive phase of treatment and
this is termed as DOTS (Directly Observed Treatment,
Short-course). It is expected that RNTP should achieve
a cure rate of 85% of infectious detected cases and a
detection rate of 70% of all infectious cases. A wellknit
monitoring system will be an integral part of the revised
strategy. Even though the World Bank is expected to
finance the project, it has not spelt out how supervision
of each patient can be achieved in a country like Ours
without taking into consideration the local situations.
As patient adherence to treatment is one of the
key factors for successful management of TB patients,
intensive research is needed to reduce the duration of
treatment to one or three months using newer drugs or
immunotherapy (56,57). It had been previously shown
that three months treatment with potent anti-TB drugs
had acheived bacteriological conversion at the end of
treatment in virtually all patients, but the relapse rate was
high (58). Other important research needs in TB include
improvement of the diagnosis of sputum smear negative
adult and childhood pulmonary tuberculosis, impact of
HIV infection on tuberculosis, role of preventive treatment
in different high risk situations especially HIV/TB,
involvement of private medical sector in TB control,
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reason why Only some people infected with
M. tuberculosis develop disease and some treated
successfully develop relapse, development of new
vaccines, role of mycobacteria in other chronic
granulomatous d iseases  (eg .  sarco idos is ) ,
understanding the molecular basis of resistance
mechanisms to anti-TB drugs, new drug targets and
development of new drugs especially from ayurvedic
system of medicine (59).
Even though medical profession is trying hard to
achieve control of TB, it can be a reality only if there is
strong political will and support for the control
programme.
1.
2.
3
4.
5.
6.
7
8.
9.
10.
11.
12
Dr. VK. Vijayan,
Cardio-Pulmonary Medicine,
TRC, ICMR, Madras 600 031.
REFERENCES
World Health Organisation Global Tuberculosis Programme.
Tuberculosis and HIV Research : Working towards solutions.
Geneva 1995; 1-23.
Leading article : The Global tuberculosis situation and the
new control strategy of the World Health Organisation.
Tubercle 1991; 72: 1-6.
Raviglione MC, Snider DE and Kochi A. Global epidemiology
of tuberculosis : morbidity and mortality of a Worldwide
epidemic. J Am Med Assoc 1992; 273: 220-6.
Dolin PJ, Raviglione MC and Kochi A. Global tuberculosis
incidence and mortality during 1990-2000. Bull Wld Hlth Org
1994; 72: 213-20.
Dhanragir H : The changing spectrum of tuberculosis.
Excerpta Medica 1995 ; 2-32.
World Health Organisation Press Release (WHO/22) 21
March 1996 ; 1-3.
Purohit SD, Gupta Rand Bhatara VK. Pulmonary tuberculosis
and HIV infection in Ajmer. Lung India 1996, 14 : 113-20.
Mahbubani V. Trikannad V and Sainani GS. Estimation of
T4/T8 ratio in patients with sarcoidosis, diffuse interstitial
pulmonary fibrosis and pulmonary tuberculosrs. Lung lndia
1996, 14 : 121-4
Vidyasagar B, Venkatesh V and Ajith Kumar. Lower lung field
tuberculosis. Lung India 1996 ; 71: 125-7
Tuberculosis chemotherapy centre : A concurrent comparison
of Home and Sanatorium treatment of pulmonary tuberculosis
in South India. Bull Wld Hlth Org 1959; 21 : 51-144.
Tuberculosis chemotherapy centre : A concurrent comparison
of intermittent (Twice-weekly) isoniazid plus streptomycin and
daily isoniazid plus PAS in the domiciliary treatment of
pulmonary tuberculosis. Bull Wld Hlth Org 1964; 31 : 247-71.
Mitchison DA Examination of sputum by smear and
culture in case finding. Bulletin Int Union Against Tub 1968
; 41: 139-51
13.
14.
15.
16.
17.
18.
19.
20.
21.
22.
23.
24
25.
26.
27.
28.
29.
30.
111
Tuberculosis Prevention Trial, Madras. Trial of BCG vaccines
in south India for tuberculosis preventron. Indian J Med Res
1980 ; 72 (Suppl) : 1-74.
Piot MA. Outline of a District Tuberculosis Programme. lndian
J Tub 1961 ; 9 : 151-6.
Nagpaul DR. Viswanath MK and Dwarakanath G A
Socioepidemiological study of out - patients attending a city
tuberculosis clinic in lndia to judge the place of specialized
centres in a tuberculosis programme. Bull Wld Hlth Org 1970
; 43 : 17-34.
Grzybowski S. Drugs are not enough. Tuber Lung Dis 1993;
74 : 145-6.
Stern DS, Korvick JA and Vermund SH. CD4 + lymphocyte
cell enumeration for prediction of clinical course of human
immunodeficiency virus disease A review. J Inf Dis 1992;
165: 352-63.
Gable M. Multidrug resistant tuberculosis. Karger Gazette
1996; 60 : 6-8.
Medun GV and Stern DS. Pulmonary manifestations of
acquired immunodeficiency syndrome. Clin Inf Dis 1992; 14
98-113.
Elliott AM, Luo N, Tembo G, Halwiindi B, Steenbergen G,
Machiels L, Pobee J, Nunn P, Hayes RJ and MC Adam KPWJ.
The impact of HIV on tuberculosis in Zambia. A cross -
sectional study. Br Med J 1990 ; 301 : 412-5.
Nunn P, Kibuga D, Gathua S, Brindle R, lmalingat A, Wasunna
K, Lucas S, Gilks C, Omwega M, Were J and Mc Adam K.
Cutaneous hypersensitivity reactions due to thiacetazone in
HIV-1 seropositive patients treated for tuberculosis. Lancet
1991, 337 : 627-30
Zhang Y, Nakata K, Weiden M and Rom WN. Mycobacterium
tuberculosis enhances human immunodeficiency virus-1
replication by transcriptional activation at the long terminal
repeat, J Clin Invest 1995; 95 : 2324-31
Pape JW, Jean SS, Ho JL, Hafner A and Johnson Jr WD.
Effect of isoniazid prophylaxis on incidence of active
tuberculosis and progression of HIV infection. Lancet 1993;
342 : 268-72.
Snider DE Jr. The relationship between tuberculosis and
silicosis (Editorial). Am Rev Respir Dis 1978; 118 : 455-60
Kaplan MH, Armstrong D and Rosen P. Tuberculosis
complicating neoplastic diseases : a review of 201 cases.
Cancer 1974 : 33 : 850 -8.
Bedall AC, Hill FGH and George RH. Hemophilia and
tuberculosis. Lancet 1983 : i : 1226.
Rutsky EA and Rostand SG. Mycobacteriosis in patients with
chronic renal failure. Arch Intern Med 1980 ; 140 : 57-61
Snider DE Jr. Tuberculosis and body build (Editorial). J Am
Med Assoc 1987 ; 258 : 3299.
Snider DE Jr. Tuberculosis and gastrectomy (Editorial). Chest
1985; 87: 414-5
Boucot KR, Dillon ES, Cooper DA and Meier P. Tuberculosis
among diabetics. The Philadelphia Survey. Am Rev Tuberc
1952; 65 (Suppl) 1-50.
112
31.
32.
33.
34.
35.
36.
37.
38.
39.
40.
41.
42.
43.
44.
45.
46.
Snider DE Jr. Jejunoileal bypass for obesity : a risk factor for
tuberculosis (Editorial). Chest 1982 ; 81 : 531-2.
Mehra NK and Bovornkitti S. HLA and tuberculosis : a
reappraisal : Asian Pac J Allergy lmmunol 1986 : 4 : 49-56
Overfield T and Klauber MR. Prevalence of tuberculosis
in Eskimos having blood group B gene. Hum Biol 1980;
52 : 87-92.
Yu G, Hsiech C and Peng J. Risk factors associated with the
prevalence of pulmonary tuberculosis among sanitary workers
in Shanghai. Tubercle 1988; 69 : 105-12.
Ruml D and Haelig AW. Activation of tuberculosis during
prednisolone therapy. Am Rev Respir Dis 1957; 76 : 140-3.
Snider DE Jr. Pregnancy and tuberculosis. Chest 1984; 86
(Suppl) : 10s-13s.
Flick JA. Does measles really predispose to tuberculosis ?
(Editorial). Am Rev Respir Dis 1976; 114: 257-65.
American Thoracic Society and Centre for Disease control.
Diagnostic standards and classification of tuberculosis. Am
Rev Respir Dis 1990 ; 142 : 725-35.
Middlebrook G, Reggiardo Z and Tigertt WD. Automatable
radiometric detection of growth of Mycobacterium tuberculosis
in selective media. Am Rev Respir Dis 1977; 115 : 1066-9.
Shinnick TM and Good RC. Diagnostic Mycobacteriology
Laboratory Practices. Clin Infect Dis 1995 ; 21 : 291-9.
Bothamley GH. Serological diagnosis of tuberculosis. Eur
Respir J 1995 ; 8 (Suppl) : 676s-688s.
Somu N, Swaminathan S, Paramasivan CN, Vijayasekharan
D, Chandrabhooshanam A, Vijayan VK and Prabhakar R.
Value of bronchoalveolar lavage and gastric lavage in the
diagnosis of pulmonary tuberculosis in children. Tuberc Lung
Dis 1995 ; 76 : 295-9.
lseman MD. Treatment of multidrug - resistant tuberculosis
N Engl J Med 1993; 329 : 784-91.
Cole ST and Telenti A. Drug resistance in Mycobacterium
tuberculosis. Eur Respir J 1995 ; 8 (Suppl 20) : 701s-713s.
Trivedi SS and Desai SG. Primary antituberculosis drug
resistance and acquired rifampicin resistance in Gujarat, India.
Tubercle 1988; 69 : 37-42.
Jain SK, Chopra KK, and Prasad G. Initial and acquired
isoniazid and rifampicin resistance in M. tuberculosis and
its implication for treatment. Ind J Tub 1992 ; 39 : 321-4.
47.
48.
49.
50.
51.
52.
53.
54.
55.
56.
57.
58.
59.
Lung India (1996), XIV, No.3 (P 109 - 112)
Paramasivan CN, Chandrasekaran V, Santha T, Sudarsanam
NM and Prabhakar R. Bacteriological investigations for short
course chemotherapy under the tuberculosis programme in
two districts in India. Tuber Lung Dis 1993 : 74 : 23-27.
Fox W. Whither short-course chemotherapy ? Br J Dis Chest
1981 ; 75 : 331-57.
Murray C, Dejonghe E, Chum HJ, Nyangulu DS, Salomao A
and Styblo K. Cost effectiveness of chemotherapy for
pulmonary tuberculosis in three sub-saharan African
countries. Lancet 1991 ; 338 : 1305-8
Grassi C and Peona V. New drugs for tuberculosis. Eur Respir
J 1995 ; 8 (Suppl 20) : 714s-718s.
Ad Hoc committee of the Scientific Assembly on Microbiology,
Tuberculosis and Pulmonary infections. Treatment of
tuberculosis and tuberculosis infection in adults and children
Ciin Inf Dis 1995 ; 21 : 9-27.
Lancet conference : the challenge of tuberculosis
Statements on global control and prevention. Lancet 1995
; 346 : 809 - 19.
Fine PEM and Rodrigues LC. Modern vaccines
Mycobacterial diseases. Lancet 1990 : 335 : 1016-20
Tripathy SP. The case for BCG. Ann Natl Med Sci 1983 ; 19
: 11-21.
Mukherjee AK. tuberculosis control programme in India :
Progress and Prospects. Ind J Tub 1995 ; 42 : 75-85.
Grange JM : Leading article : Immunotherapy of tuberculosis
Tubercle 1990 ; 71 : 237-9.
Stanford JL, Grange JM and Pozniak A. Is Africa Lost ? Lancet
1991 ; 338 : 557-8.
Balasubramanyam R, Sivasubramaniam S, Vijayan VK,
Ramachandran R, Jawahar MS, Paramasivan CN,
Selvakumar N and Somasundaram PR. Five year results of
a 3 month and two 5 - month regimens for the treatment of
smear - positive pulmonary tuberculosis in south India.
Tubercle 1990 ; 71 : 253-8,
Sharma VK. Tuberculostatic activity of henna (Lawsonia
inermis Linn.) Tubercle 1990 ; 71 : 293-5.
